Literature DB >> 28445663

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Xavier Montalban1, Shibeshih Belachew2, Jerry S Wolinsky3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28445663     DOI： 10.1056/NEJMc1702076

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Aged hind-limb clasping experimental autoimmune encephalomyelitis models aspects of the neurodegenerative process seen in multiple sclerosis.

Authors:  Lindsay S Cahill; Monan Angela Zhang; Valeria Ramaglia; Heather Whetstone; Melika Pahlevan Sabbagh; Tae Joon Yi; Laura Woo; Thomas S Przybycien; Marina Moshkova; Fei Linda Zhao; Olga L Rojas; Josephine Gomes; Stefanie Kuerten; Jennifer L Gommerman; John G Sled; Shannon E Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-22       Impact factor: 11.205

Review 2.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 3.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

4.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

5.  Drug repurposing for neuroregeneration in multiple sclerosis.

Authors:  Patrick Küry; David Kremer; Peter Göttle
Journal:  Neural Regen Res       Date:  2018-08       Impact factor: 5.135

6.  Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.

Authors:  Gisa Ellrichmann; Jan Bolz; Maren Peschke; Alexander Duscha; Kerstin Hellwig; De-Hyung Lee; Ralf A Linker; Ralf Gold; Aiden Haghikia
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

7.  Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS.

Authors:  Darius Häusler; Zivar Hajiyeva; Jan W Traub; Scott S Zamvil; Patrice H Lalive; Wolfgang Brück; Martin S Weber
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-17

8.  CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.

Authors:  Darius Häusler; Katja Akgün; Lidia Stork; Hans Lassmann; Tjalf Ziemssen; Wolfgang Brück; Imke Metz
Journal:  Brain Pathol       Date:  2021-05-06       Impact factor: 6.508
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.